Skip to Content
Merck
  • Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking.

Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking.

Biochemical and biophysical research communications (2013-09-10)
Young In Sohn, Nathanael J Lee, Andrew Chung, Juan M Saavedra, R Scott Turner, Daniel T S Pak, Hyang-Sook Hoe
ABSTRACT

Recent studies demonstrated that the antihypertensive drug Valsartan improved spatial and episodic memory in mouse models of Alzheimer's Disease (AD) and human subjects with hypertension. However, the molecular mechanism by which Valsartan can regulate cognitive function is still unknown. Here, we investigated the effect of Valsartan on dendritic spine formation in primary hippocampal neurons, which is correlated with learning and memory. Interestingly, we found that Valsartan promotes spinogenesis in developing and mature neurons. In addition, we found that Valsartan increases the puncta number of PSD-95 and trends toward an increase in the puncta number of synaptophysin. Moreover, Valsartan increased the cell surface levels of AMPA receptors and selectively altered the levels of spinogenesis-related proteins, including CaMKIIα and phospho-CDK5. These data suggest that Valsartan may promote spinogenesis by enhancing AMPA receptor trafficking and synaptic plasticity signaling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Valsartan, ≥98% (HPLC)
Sigma-Aldrich
Monoclonal Anti-Synaptophysin antibody produced in mouse, clone SVP-38, ascites fluid
Valsartan, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anti-phospho-CREB (Ser133) Antibody, Upstate®, from rabbit
Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard